Evotec AG (NASDAQ:EVO – Get Free Report) traded up 2.7% during mid-day trading on Wednesday . The stock traded as high as $2.76 and last traded at $2.69. 21,810 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 32,857 shares. The stock had previously closed at $2.62.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on EVO. Wall Street Zen lowered shares of Evotec from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright assumed coverage on Evotec in a report on Wednesday, April 15th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Weiss Ratings raised Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.
Check Out Our Latest Stock Analysis on EVO
Evotec Stock Up 1.7%
Evotec (NASDAQ:EVO – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.05 EPS for the quarter. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%.The business had revenue of $297.02 million for the quarter. As a group, equities research analysts expect that Evotec AG will post -0.63 earnings per share for the current year.
Institutional Investors Weigh In On Evotec
Several large investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in Evotec by 25.7% during the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock valued at $5,536,000 after purchasing an additional 367,545 shares during the last quarter. DCF Advisers LLC increased its holdings in shares of Evotec by 7.6% during the third quarter. DCF Advisers LLC now owns 1,198,993 shares of the company’s stock worth $4,352,000 after buying an additional 84,500 shares in the last quarter. WCM Investment Management LLC increased its holdings in shares of Evotec by 12.1% during the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after buying an additional 67,917 shares in the last quarter. ABC Arbitrage SA raised its stake in shares of Evotec by 319.7% in the fourth quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock valued at $1,707,000 after acquiring an additional 422,230 shares during the last quarter. Finally, Optiver Holding B.V. raised its stake in shares of Evotec by 598.4% in the first quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after acquiring an additional 242,973 shares during the last quarter. Institutional investors own 5.81% of the company’s stock.
Evotec Company Profile
Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.
Featured Articles
- Five stocks we like better than Evotec
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
